The purpose of this study was to assess whether dynamic torque ratios (DCR) from isokinetic strength assessments of eccentric knee flexors (eccKF) and concentric knee extensors (conKE) display differences when stratified into specific angle-specific DCR (DCR) groups. Fifty-two professional female soccer players (age 21.30 ± 4.44 years; height 166.56 ± 5.17 cm; mass 61.55 ± 5.73 kg) from the English Women's Super League completed strength assessments of both lower limbs on an isokinetic dynamometer at 60°∙s Angle-specific torque (AST) were used to calculate DCR to create sub-groups using clustering algorithms. The results identified for the dominant side that the Medium DCR group elicited significantly higher conKE AST when compared to Low and High DCR groups at increased knee extension ( ≤ 0.05). For the non-dominant side, the High DCR group had significantly higher and lower eccKF and conKE AST compared to the Low DCR group at increased knee extension ( ≤ 0.05). This study highlights that the inclusion of AST data may subsequently help practitioners to prescribe exercise that promotes strength increases at targeted joint angles. In turn, these approaches can be used to help reduce injury risk, identify rehabilitation responses and help inform return to play.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/02640414.2022.2061251 | DOI Listing |
J Craniofac Surg
January 2025
National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, China.
Aim: This research was designed to make a comparison of the treatment outcomes of endoscopic dacryocystorhinostomy (En-DCR) in nasolacrimal duct obstruction (NLDO) with and without chronic dacryocystitis.
Methods: NLDO (obstruction group) and chronic dacryocystitis (dacryocystitis group) patients treated with En-DCR in the Eye Hospital of Wenzhou Medical University from March 2021 to February 2022 were retrospectively analyzed. According to CT dacryocystography, patients in each group were assigned into the high obstruction group (obstruction located in the lacrimal sac) and the low obstruction group (obstruction located at or below the junction of the nasolacrimal duct and dacryocystis).
Cancer Rep (Hoboken)
January 2025
Department of Oncology, The First Hospital of Lanzhou University, Lanzhou, China.
Objective: This study aims to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in treating small-cell lung cancer (SCLC) and determine the role of PD-1 monoclonal antibodies in improving patient outcomes.
Methods: A retrospective analysis was performed on 37 SCLC patients who received PD-1 or PD-L1 inhibitors along with chemotherapy at the First Hospital of Lanzhou University between June 2018 and June 2023. Treatment effectiveness was measured by overall response rate (ORR), disease control rate (DCR), overall survival (OS), and progression-free survival (PFS), utilizing chi-square and T-tests, along with Kaplan-Meier and log-rank analyses.
Cancer Treat Rev
January 2025
Division of Hematology and Oncology, University of Virginia Comprehensive Cancer Center, Charlottesville, VA, United States. Electronic address:
Background: Trastuzumab deruxtecan (T-DXd) has shown promising activity in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) and central nervous system (CNS) involvement. In this updated meta-analysis, we explore the effectiveness of T-DXd in a large subset of patients with HER2-positive BC and CNS disease.
Methods: A systematic search was made on September 16th, 2024, for studies investigating T-DXd in the scenario of HER2-positive BC and brain metastases (BMs) and/or leptomeningeal disease (LMD).
Ther Adv Med Oncol
January 2025
Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, No. 138, Sheng Li Road, Tainan 704, Taiwan.
Background: Infiltrative hepatocellular carcinoma (HCC) is often associated with an unfavorable prognosis, posing a challenge in determining the optimal therapeutic approach. Immunotherapy, employing immune checkpoint inhibitors (ICIs), has become a preferred first-line treatment for advanced HCC. However, the overall effectiveness of ICIs in patients with infiltrative HCC remains unclear.
View Article and Find Full Text PDFTumori
January 2025
Department of Otolaryngology, Shaoxing People's Hospital, Shaoxing, China.
Background: The combination of programmed cell death protein 1 (PD-1) inhibitors and chemotherapy has shown promising results in the treatment of various malignancies. This meta-analysis aims to evaluate the effectiveness and safety of combing PD-1 inhibitor with chemotherapy in patients with advanced NPC.
Methods: A thorough search of the literature was carried out using comprehensive methods.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!